Boston Biomedical Science
Boston Biomedical is committed to advancing a pipeline of agents to treat solid tumors and hematologic malignancies. We are focused on areas of unmet need in oncology research and development, including cancer stemness pathways and prioritized tumor antigens. By addressing drivers of treatment resistance and tumor progression in the context of the tumor microenvironment, our approach aims to expand the range of cancer treatment options available to patients.
At Boston Biomedical, our most advanced clinical programs currently are evaluating agents that are hypothesized to target cancer stemness and tumors expressing the Wilms’ tumor protein 1 (WT1).